Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing DiscoveriesDuring the past decade there has been a significant transformation in the care of patients with advanced prostate cancer. New insights into the diseases biology and mechanisms of castration ...
Taking into context that this is a very active drug that improved survival for patients with metastatic hormone-sensitive prostate cancer, this is a drug that people will end up staying on for a significant amount of time. When we look at the study, the median treatment duration for someone ...
Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type or stage of prostate cancer in which the cancer has spread outside of the prostate—that's the metastatic term—and hormone-sensitive means that it hasn't yet been treated with androgen deprivation the...
The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT). Historically, in a time when systemic therapy options ...
A 75-year-old Man with Prostate Cancer: Episode1 ByAlicia K. Morgans, MD, MPH Video Expert oncologist Alicia Morgans, MD, MPH, shares details on the diagnosis and management of a patient with metastatic castration-resistant prostate cancer. ...
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies have demonstrated durable remissions in hematological malignancies. We report results from a pha
11 To our knowledge, all studies evaluating luminal/basal subtypes within prostate cancer have been limited to primary prostate cancer tissue, in part due to the difficulties in obtaining biopsies from metastases, which are often confined to bone. Metastatic castration-resistant prostate cancer (mCRPC...
Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancereribulincastrate resistant prostate cancermicrotubule inhibitorEribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. ...
In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer. In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD, medical oncologist,...